financetom
Business
financetom
/
Business
/
M/i Homes Insider Sold Shares Worth $2,342,400, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
M/i Homes Insider Sold Shares Worth $2,342,400, According to a Recent SEC Filing
Apr 30, 2024 2:02 PM

04:34 PM EDT, 04/30/2024 (MT Newswires) -- Robert H Schottenstein, Director, Chairman, CEO & President, on April 29, 2024, sold 19,200 shares in M/i Homes ( MHO ) for $2,342,400. Following the Form 4 filing with the SEC, Schottenstein has control over a total of 122,951 shares of the company, with 122,951 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/799292/000079929224000043/xslF345X03/wk-form4_1714508030.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CME Group Board Approves $3 Billion Stock Buyback Plan, $2.10 Billion Annual Variable Dividend
CME Group Board Approves $3 Billion Stock Buyback Plan, $2.10 Billion Annual Variable Dividend
Dec 5, 2024
07:50 AM EST, 12/05/2024 (MT Newswires) -- CME Group ( CME ) said Thursday its board approved an annual variable dividend totaling $2.10 billion as well as a share repurchase program of up to $3 billion of Class A common stock. The dividend amounts to $5.80 per share and is payable Jan. 16, 2025, to shareholders of record as of...
Merck Begins Late-Stage Trial to Evaluate Lagevrio for Treatment of COVID-19 in High-Risk Adults
Merck Begins Late-Stage Trial to Evaluate Lagevrio for Treatment of COVID-19 in High-Risk Adults
Dec 5, 2024
07:47 AM EST, 12/05/2024 (MT Newswires) -- Merck ( MRK ) said Thursday that it has started a late-stage clinical trial to assess investigational oral antiviral COVID-19 medicines Lagevrio or molnupiravir for the treatment of adults with COVID-19 who are at high risk for disease progression. Lagevrio is being developed by Merck ( MRK ) in collaboration with Ridgeback Biotherapeutics....
Patterson Companies Fiscal Q2 Adjusted Earnings Down, Sales Rise; Lowers Fiscal 2025 Adjusted EPS Guidance
Patterson Companies Fiscal Q2 Adjusted Earnings Down, Sales Rise; Lowers Fiscal 2025 Adjusted EPS Guidance
Dec 5, 2024
07:45 AM EST, 12/05/2024 (MT Newswires) -- Patterson Companies ( PDCO ) reported fiscal Q2 adjusted earnings Thursday of $0.47 per diluted share, down from $0.50 a year earlier. A single analyst polled by FactSet expected $0.47. Net sales for the fiscal quarter ended Oct. 26 was $1.67 billion, up from $1.65 billion a year earlier. Analysts surveyed by FactSet...
Southwest Airlines Raises Q4 Revenue Guidance Amid Strong Leisure Travel Demand
Southwest Airlines Raises Q4 Revenue Guidance Amid Strong Leisure Travel Demand
Dec 5, 2024
07:45 AM EST, 12/05/2024 (MT Newswires) -- Southwest Airlines ( LUV ) said in a regulatory filing Thursday that it increased its Q4 unit revenue growth forecast to a range of 5.5% to 7% from the previous range of 3.5% to 5.5%, citing better-than-expected leisure travel demand and revenue optimization efforts. The carrier said it now expects Q4 capacity to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved